Rhumbline Advisers Adaptimmune Therapeutics PLC Transaction History
Rhumbline Advisers
- $121 Billion
- Q3 2025
A detailed history of Rhumbline Advisers transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 5,743 shares of ADAP stock, worth $172. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,743
Previous 8,533
32.7%
Holding current value
$172
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ADAP
# of Institutions
63Shares Held
42MCall Options Held
139KPut Options Held
144K-
Long Focus Capital Management, LLC San Juan, PR18.6MShares$557,3340.1% of portfolio
-
Ubs Group Ag6.67MShares$200,0200.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.05MShares$121,6220.0% of portfolio
-
Morgan Stanley New York, NY3.67MShares$109,9810.0% of portfolio
-
Jane Street Group, LLC New York, NY2.81MShares$84,1600.0% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $4.9M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...